KaloBios Pharmaceuticals Inc. (KBIO) Financials Nov 14, 2014, 4:00 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for KaloBios Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 589,000 17.71M 20.26M 6.1M 44,000
Cost of Goods Sold (COGS) incl. D&A 844,000 843,000 595,000 304,000 -
COGS excluding D&A 0 0 0 0 -
Depreciation & Amortization Expense 844,000 843,000 595,000 304,000 298,000
Depreciation 733,000 732,000 484,000 193,000 298,000
Amortization of Intangibles 111,000 111,000 111,000 111,000 0
Gross Income (255,000) 16.87M 19.66M 5.79M -
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 27.21M 22.99M 20.83M 29.28M 40.66M
Research & Development 22.86M 18.89M 17.61M 24.52M 32.64M
Other SG&A 4.35M 4.1M 3.22M 4.76M 8.02M
Other Operating Expense 0 0 0 0 0
Unusual Expense - (2,000) 1.15M 39,000 0
EBIT after Unusual Expense - 2,000 (1.15M) (39,000) 0
Non Operating Income/Expense 348,000 913,000 40,000 152,000 (39,000)
Non-Operating Interest Income 291,000 108,000 43,000 45,000 86,000
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense - - - 185,000 1.09M
Gross Interest Expense - - - 185,000 1.09M
Interest Capitalized 0 0 0 0 0
Pretax Income (26.82M) (5.1M) (2.23M) (23.51M) (41.95M)
Income Tax (19,000) 0 0 0 0
Income Tax - Current Domestic - 0 0 - -
Income Tax - Current Foreign - 0 0 - -
Income Tax - Deferred Domestic - 0 0 - -
Income Tax - Deferred Foreign - 0 0 - -
Income Tax Credits - 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (26.81M) (5.1M) (2.23M) (23.51M) (41.95M)
Minority Interest Expense 0 0 0 0 0
Net Income (26.81M) (5.1M) (2.23M) (23.51M) (41.95M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (26.81M) (5.1M) (2.23M) (23.51M) (41.95M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (26.81M) (5.1M) (2.23M) (23.51M) (41.95M)
EPS (Basic) (1.11) (0.21) (0.09) (11.22) (1.73)
Basic Shares Outstanding 24.13M 24.13M 24.13M 2.1M 24.27M
EPS (Diluted) (1.11) (0.21) (0.09) (11.22) (1.73)
Diluted Shares Outstanding 24.13M 24.13M 24.13M 2.1M 24.27M
EBITDA (26.62M) (5.28M) (572,000) (23.18M) (40.61M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for KaloBios Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 589,000 17.71M 20.26M 6.1M 44,000
Cost of Goods Sold (COGS) incl. D&A 844,000 843,000 595,000 304,000 -
COGS excluding D&A 0 0 0 0 -
Depreciation & Amortization Expense 844,000 843,000 595,000 304,000 298,000
Depreciation 733,000 732,000 484,000 193,000 298,000
Amortization of Intangibles 111,000 111,000 111,000 111,000 0
Gross Income (255,000) 16.87M 19.66M 5.79M -
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 27.21M 22.99M 20.83M 29.28M 40.66M
Research & Development 22.86M 18.89M 17.61M 24.52M 32.64M
Other SG&A 4.35M 4.1M 3.22M 4.76M 8.02M
Other Operating Expense 0 0 0 0 0
Unusual Expense - (2,000) 1.15M 39,000 0
EBIT after Unusual Expense - 2,000 (1.15M) (39,000) 0
Non Operating Income/Expense 348,000 913,000 40,000 152,000 (39,000)
Non-Operating Interest Income 291,000 108,000 43,000 45,000 86,000
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense - - - 185,000 1.09M
Gross Interest Expense - - - 185,000 1.09M
Interest Capitalized 0 0 0 0 0
Pretax Income (26.82M) (5.1M) (2.23M) (23.51M) (41.95M)
Income Tax (19,000) 0 0 0 0
Income Tax - Current Domestic - 0 0 - -
Income Tax - Current Foreign - 0 0 - -
Income Tax - Deferred Domestic - 0 0 - -
Income Tax - Deferred Foreign - 0 0 - -
Income Tax Credits - 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (26.81M) (5.1M) (2.23M) (23.51M) (41.95M)
Minority Interest Expense 0 0 0 0 0
Net Income (26.81M) (5.1M) (2.23M) (23.51M) (41.95M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (26.81M) (5.1M) (2.23M) (23.51M) (41.95M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (26.81M) (5.1M) (2.23M) (23.51M) (41.95M)
EPS (Basic) (1.11) (0.21) (0.09) (11.22) (1.73)
Basic Shares Outstanding 24.13M 24.13M 24.13M 2.1M 24.27M
EPS (Diluted) (1.11) (0.21) (0.09) (11.22) (1.73)
Diluted Shares Outstanding 24.13M 24.13M 24.13M 2.1M 24.27M
EBITDA (26.62M) (5.28M) (572,000) (23.18M) (40.61M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
